CD19 and hematologic disorder: Current immunotherapies targeting CD19-expressing hematological malignancies, such as CAR T cells and BiTEs, inherently bypass cognate TCR/pHLA-I signaling and consequently induce the non-physiological hyperactivation of T cells.